Today's Healthcare Pulse
FDA greenlights durvalumab combo for high‑risk bladder cancer
The FDA approved durvalumab (Imfinzi) combined with Bacillus Calmette‑Guerin for BCG‑naïve, high‑risk non‑muscle invasive bladder cancer. The POTOMAC trial enrolled 1,018 patients and showed a 32% reduction in disease recurrence risk (hazard ratio 0.68, p=0.015). Durvalumab is given at 1,500 mg IV every four weeks for up to 13 cycles.
Also developing:
By the numbers: Apogee Therapeutics raises $1.3B royalty financing
Hospitals Are Treating Burnout as a Wellness Problem. It Is an Operating Model Problem
Hospitals treat physician burnout as a wellness issue, but the root cause is an operating model that piles administrative load, financial risk, and decision‑making away from clinicians. Studies show wellness interventions have little impact, while physicians now spend 15‑25 hours per week on non‑clinical tasks and burnout rates hover around 40%. AI tools save only minutes of documentation and do not address the underlying structural problems. Executives must measure admin burden, shift tasks to staff, grant clinicians real decision authority, and adjust compensation to retain physicians.
Glooko Announces FDA 510(k) Clearance for EndoTool IV Cloud
Glooko announced that the U.S. Food and Drug Administration granted 510(k) clearance for EndoTool IV Cloud, the first cloud‑based, patient‑specific insulin dosing platform for hospitals. The solution mirrors the proven algorithm of the on‑premise EndoTool IV but adds scalable, centralized deployment and reduced...
EP511: The Tension When Clinical Teams Take On Risk for Policymakers and Others Looking to Rustle Up Future Perverse Incentives,...
In this episode, Dr. Siva and Dr. Monica Lypson discuss the perverse incentives created when clinical teams assume financial risk in value‑based contracts, especially around upcoding, downcoding, and the resulting cherry‑picking or "lemon‑dropping" of patients. They argue that without transparent,...
Ontario to Let Pharmacists Administer More Vaccines, Prescribe for More Ailments
Ontario announced a July 2026 expansion of pharmacists' scope, allowing them to administer six publicly funded vaccines—including tetanus, RSV and shingles—and to assess and prescribe for nine common minor ailments such as dandruff and mild headache. Pharmacy technicians will also...
Judge Blocks Trump Administration’s Demand for Rhode Island Hospital's Records of Transgender Kids
U.S. District Judge Mary McElroy ruled Wednesday that the Justice Department’s subpoena demanding Rhode Island Hospital’s records on transgender minors is invalid. The demand covered birth dates, Social Security numbers, addresses, treatment notes and side‑effect reports for five years of...
The Leaders Closing the Gap: How Strong Healthcare Administrators Are Driving Technology Transformation
Healthcare administrators are now the primary drivers of technology transformation, leveraging the operational lessons learned from decade‑long EHR deployments. Their expertise in budgeting, workflow redesign, and stakeholder alignment is enabling AI, integrated platforms, and advanced analytics to move from pilot...
Roche Rolls Out Tecentriq SC Immunotherapy for Lung Cancer with the Promise of Less Treatment Time
Roche has launched its sub‑cutaneous form of Tecentriq (atezolizumab) in India, offering an immunotherapy for lung cancer that can be administered in about seven minutes versus several hours for traditional IV infusions. The SC version is priced at roughly ₹3.7 lakh...
Drug Ads Are Deceptive and Deadly
The Center for Economic and Policy Research reports that U.S. pharmaceutical firms are spending more than $10 billion a year on direct‑to‑consumer drug advertising, often using misleading claims to boost sales. These deceptive ads have been shown to increase prescription rates...
Why Pharma Is Rethinking the Centralized Hub Model
Pharma companies are abandoning the legacy centralized hub model in favor of a tech‑enabled “hubless hub” that distributes access functions across digital platforms and specialized partners. The shift is driven by the growing complexity of specialty therapies, tighter payer requirements,...
AstraZeneca Follows Merck with Phase 3 Win in Bladder Cancer
AstraZeneca announced that its checkpoint inhibitor Imfinzi, co‑developed with Pfizer, combined with Astellas’ antibody‑drug conjugate Padcev, significantly extended overall survival in a Phase 3 trial for advanced bladder cancer. The regimen outperformed the current standard of care, marking the company’s second...
Cyclarity Unveils Oxidized Cholesterol Excretion Data
Cyclarity Therapeutics presented Phase 1 data for UDP-003, its cyclodextrin drug that binds and removes oxidized cholesterol (7‑ketocholesterol) from humans. The Monash Victorian Heart Institute trial showed dose‑dependent urinary excretion of 7KC, with no serious adverse events and a short...
'We're Right on Track,' Says Streeting as Key Target for Hospital Waiting Times Hit
The UK government met its interim NHS waiting‑time target, with 65.3% of patients treated within 18 weeks, just above the 65% goal for March 2026. The figure rose from under 59% when Labour took power and coincided with the overall waiting...
MacroGenics Sells Manufacturing Arm; West Pharma Discloses Cybersecurity Attack
MacroGenics announced the sale of its GMP‑manufacturing operations to Bora Pharmaceuticals, shifting its focus back to early‑stage antibody development. The transaction, terms undisclosed, transfers a fully qualified production suite and associated staff. In parallel, West Pharma disclosed a recent cybersecurity...
Health Secretary RFK Jr. Unveils Plan to Curb Psychiatric Medication Overprescribing
U.S. Health and Human Services Secretary Robert F. Kennedy Jr. announced a nationwide plan to curb the overprescribing of psychiatric medications, especially among children. The initiative calls for informed consent, shared decision‑making, and greater use of non‑pharmacologic treatments. Experts praised...
Orforglipron Enables Over 70% Weight‑Loss Maintenance After GLP‑1 Injections, Phase 3 Trial Shows
In the ATTAIN‑MAINTAIN phase 3 trial, adults who switched from injectable semaglutide or tirzepatide to the oral GLP‑1 agonist orforglipron kept over 70% of their weight loss after one year. The study, presented at the European Congress on Obesity, highlights...
Our Aging Population Is Forcing a Rethink of How We Design & Package Medicines
Biopharma must redesign medicines for an aging population, as adults 65+ are rapidly growing and 89% of U.S. seniors use at least one prescription. Legacy child‑resistant packaging creates usability challenges, prompting the rise of child‑resistant, senior‑friendly (CRSF) solutions. Early integration...
Eli Lilly’s Weight‑loss Dominance Challenged by Oral GLP‑1 and Dose‑reduction Options
Eli Lilly announced Phase 3b results showing its oral GLP‑1 drug Foundayo and lower‑dose Zepbound can preserve most weight loss after switching from higher‑dose injectables. The data intensify competition within Lilly’s own portfolio and signal rising pressure from oral agents and rivals...
The ACCESS Model’s Behavioral Health Track
The CMS Innovation Center’s ACCESS Model launches on July 5 2026 with a behavioral health (BH) track that pays $180 per beneficiary in the Initial Period and $90 in the Follow‑On Period, contingent on meeting PHQ‑9 or GAD‑7 improvement thresholds. The track...
Oregon’s Anti‑Consolidation Law Remains Unused After Five Years
Oregon’s 2021 statute that empowers the state health department to block hospital, hospice and medical‑practice deals has not blocked a single transaction or issued fines in five years. The law, hailed as a national model, has only prompted the withdrawal...
How Remote Patient Monitoring Can Alleviate Staffing Strain and Improve Healthcare Delivery
Hospitals facing staffing shortages turn to remote patient monitoring (RPM) to extend care capacity. RPM integrates with major EHRs, delivering real‑time vitals and automating admin tasks so clinicians can focus on high‑need patients. Evidence from UPMC shows Medicare participants were...
How Capital Costs Make It Near-Impossible to Be an Independent Physician
A new report highlights how soaring capital costs are pushing independent physicians out of business. Consolidation by hospital systems, insurers, and private‑equity firms has squeezed small practices, forcing them to seek expensive, often predatory financing. The analysis shows independent doctors...
Response to Infectious Diseases Caused by Hantaviruses in Japan
A BMJ rapid‑response letter from Japanese infectious‑disease specialists highlights a hantavirus outbreak linked to the cruise ship MV Hondius, with four Japanese passengers confirmed infected as of May 14, 2026. The World Health Organization classifies the public‑health risk as low, yet the...
How Penn Medicine Plans to Use AI to Train Their Doctors
Penn Medicine secured a $1.1 million American Medical Association education grant to develop AI‑driven tools that give medical trainees real‑time feedback on clinical reasoning. The project will deploy ambient artificial intelligence to record and analyze both peer‑to‑peer and patient‑facing conversations, using...
Reducing No Shows at Regional Practices: How Automated Communications Help Connect Patients to Care
Patient no‑shows cost U.S. providers about $150 billion annually, with an 18 % national miss rate. Regional practices, lacking the scale of large systems, feel the revenue hit most acutely. Automated, two‑way communication platforms that deliver personalized reminders via text, call or...
CMS Announces Nationwide Crackdown on Fraud with Six-Month Hospice and Home Health Agency Enrollment Moratoria
The Centers for Medicare & Medicaid Services announced a six‑month, nationwide moratorium on new Medicare enrollment for hospice and home health agencies. The pause targets high‑risk fraud by blocking fresh providers and tightening ownership‑change approvals. During the moratorium CMS will...
“Get Serious or Lose Funding”: Vance Escalates Medicaid Crackdown.
JD Vance warned that states failing to cooperate with the White House’s anti‑fraud campaign could lose Medicaid and Medicare funding, a threat that has already halted hundreds of millions of dollars in Minnesota. Critics argue the administration lacks clear statutory...
AstraZeneca Reports the P-III (VOLGA) Trial Data on Imfinzi + Enfortumab Vedotin (EV) for Muscle-Invasive Bladder Cancer
AstraZeneca presented Phase III VOLGA data showing that the combination of Imfinzi (durvalumab) and Enfortumab Vedotin improves event‑free survival and overall survival in muscle‑invasive bladder cancer patients who cannot receive cisplatin. The trial enrolled 695 patients undergoing radical cystectomy and compared two...
The World Must Not Turn Its Back on Vaccination
Global childhood immunization has stalled as financing fell up to 40 % since 2023, leaving half of the 14 million never‑vaccinated children in conflict‑affected zones. The World Health Assembly now faces a choice between renewed commitment to the most cost‑effective public‑health tool...
Employer Health Plan Facility Fees Targeted in Bipartisan House Bill
The bipartisan Transparency in Billing Act, reintroduced by Rep. Virginia Foxx and Rep. Robert Scott, seeks to stop hospitals from applying hospital‑level facility fees to services rendered in outpatient offices. The legislation would require health‑plan claims to include separate identifier...
WWL Embeds National Clinical Guidance Into Altera Digital Health’s Sunrise EPR to Transform Acute Abdomen Pathway
Wrightington, Wigan and Leigh Teaching Hospitals NHS Foundation Trust partnered with Altera Digital Health to embed National Emergency Laparotomy Audit (NELA) guidance into its Sunrise Electronic Patient Record. The integration automated decision support, one‑click CT ordering, and risk scoring, driving...
Clinical Practice Telepsychiatry Expansion Showed Limited Gains in Reaching Rural, Underserved Patients
A recent JAMA Network Open analysis of telepsychiatry programs from 2024‑2025 shows a modest 12% rise in virtual mental‑health visits, but the expansion fell short of reaching rural and underserved populations. Rural patients comprised just 8% of all telepsychiatry sessions,...
Isomorphic Labs Pulls $2.1B Series B Led By Thrive With MGX, Temasek, And UK Sovereign AI Fund: What The Capital...
Isomorphic Labs announced a $2.1 billion Series B round led by Thrive, with participation from MGX, Temasek, and the UK Sovereign AI Fund. The funding backs the company’s IsoDDE AI engine for drug discovery, despite having no approved drugs or Phase 2 data....
BeOne Wins Mantle Cell Lymphoma Approval, Opening New Therapy Class
The FDA granted accelerated approval to BeOne Medicines’ BCL2 inhibitor sonrotoclax, marketed as Beqalzi, for patients with relapsed or refractory mantle‑cell lymphoma who have failed at least two prior therapies, including a BTK inhibitor. The drug is the first BCL2...
EU Unveils $6.5B Global Health Resilience Initiative for Worldwide Security
The European Commission rolled out a Global Health Resilience Initiative, committing over €6 billion (about $6.5 billion) to reinforce health sovereignty in partner countries, streamline the multilateral health architecture and mobilise private capital for pandemic preparedness.
Alembic Pharma Gets USFDA Tentative Approval for Generic Prostate Cancer Drug
Alembic Pharmaceuticals received tentative USFDA approval for its 300 mg generic Darolutamide tablets, deemed therapeutically equivalent to Bayer’s Nubeqa. The approval applies to an Abbreviated New Drug Application, clearing a major regulatory hurdle for the Indian firm. Darolutamide targets prostate cancer...
New Healthcare Apprenticeship Initiative Puts the Focus on Employers
UW Health WorkForward, launched by former National Center for the Apprenticeship Degree leader Eric Dunker, is the first national employer‑led intermediary focused on healthcare apprenticeships. The initiative offers technical assistance, policy advocacy, and research to help hospitals and health systems...
FDA Hands BeOne, Taiho Approvals for Blood Cancers
BeOne Medicines’ BCL‑2 inhibitor Beqalzi (sonrotoclax) earned FDA accelerated approval as a third‑line treatment for mantle‑cell lymphoma, marking the first U.S. approval of a BCL‑2 drug for this indication. The approval is based on a phase 1/2 trial showing a 52%...
RGNX Shows 71% Microdystrophin, Eyes 2027 Approval
$RGNX Duchenne gene therapy study results are out: microdystrophin expression reached an average of 71% of normal across all 31 boys at 12 wks. Functional improvements in a subset of boys followed for one year also seen. The big question...
Calm Leadership: Diamantas Poised to Benefit Biotech
‘No drama’ Diamantas should serve biotech well as acting FDA chief A nice column from @adamfeuerstein, who apparently ate his Wheaties today. https://t.co/zh5CU9Sv69 via @statnews
Regulatory Round-Up: A Month of Key FDA Approvals for Cancer Drugs
The FDA approved four oncology drugs in May 2026, marking a focused regulatory push in cancer therapeutics. Taiho Oncology received clearance for the oral Inqovi‑venetoclax regimen for elderly acute myeloid leukemia patients, while BeOne Medicines earned accelerated approval for Beqalzi...
Blood Test Help Personalise Depression Treatment
NeuroKaire, an Israeli startup, has launched BrightKaire—a blood‑based test that uses patient‑derived stem cells to create frontal brain neurons and assess how 70 different antidepressants affect neural connectivity. The test, now approved in Israel and the United States, promises to...
The Beauty of Iteration
Anthony Guerra argues that iteration and low‑risk experimentation are essential for health‑system IT leaders, using his team’s evolution of raw interview recordings into SEO‑optimized YouTube Shorts as a case study. He stresses that near‑miss failures provide the richest learning, especially...
Top 7 Fastest Growing Pharma & Biotech Companies in Asia for 2026
The Financial Times’ 2026 ranking spotlights the seven fastest‑growing Asian pharma and biotech firms, each posting double‑digit revenue surges and landmark milestones. SillaJen earned an FDA IND for its oncolytic virus BAL0891, while Oscotec leveraged lazertinib royalties to boost 2024...
What’s Coming up at SLAS Europe 2026?
The Society for Laboratory Automation and Screening (SLAS) will host its 2026 European Conference and Exhibition in Vienna from May 19‑21, featuring a technology provider showcase at the Vienna BioCenter and a packed scientific program. Highlights include keynote and breakout...
EIS Officers Claim Bureaucracy Stifles Outbreak Response
This quote in @Craig_A_Spencer's piece in @statnews is most worrisome to me - suggests some of our Epidemic Intelligence Service officers feel like they're being held back from doing their jobs and responding to outbreaks. https://t.co/hAXPZpL1Om
METiS TechBio Raises $270M in Record HKEX AI‑Biotech IPO
METiS TechBio listed on the Hong Kong Stock Exchange, selling 201.23 million H‑shares for HK$2.11 billion ($270 million). The offering, underwritten by Jefferies, Deutsche Bank Securities Asia and CITIC Securities, was oversubscribed more than 6,900 times, setting a new benchmark for AI‑driven biotech...
Canada’s Fentanyl Czar Warns Newer, Deadlier Synthetics Threaten U.S. Gains
Commissioner Kevin Brosseau, Canada’s “fentanyl czar,” warned that ultra‑potent synthetic opioids such as nitazenes—up to 40 times stronger than fentanyl—are now appearing on both sides of the U.S.-Canada border. The surge threatens to undo a recent 20% decline in fentanyl‑related...
METiS TechBio's $270 M AI‑Drug Delivery IPO Sets HKEX Record
METiS TechBio listed on the Hong Kong Stock Exchange, raising HK$2.11 bn ($270 m) and becoming the world’s first publicly traded AI‑powered drug‑delivery company. The offering was oversubscribed more than 6,900 times, drawing $148 m from 18 cornerstone investors including BlackRock. The IPO...
De-CIPHER-Ing Transcriptomes and Proteins Together with New RNA-Seq Technology
Scientists at the Sylvester Comprehensive Cancer Center and UCSF unveiled CIPHER‑seq, a single‑cell platform that simultaneously measures whole‑transcriptome RNA and intracellular proteins. By optimizing fixation, permeabilization and antibody incubation, the method avoids the RNA degradation and stress artifacts that plague...
The Case for Smarter Neuroinflammation Clinical Trials
INmune Bio, led by CEO David Moss, is developing non‑immunosuppressive therapies that target innate immune pathways, including the XPro1595 program for neurodegenerative disease and the CORDStrom mesenchymal stromal cell platform for recessive dystrophic epidermolysis bullosa (RDEB). The company argues that...